The COVID-19 pandemic might seem like a distant memory for most of us, but the effects unfortunately linger for some: many people infected with COVID-19 have medium or long-term symptoms. If these symptoms last for at least three months after infection, we speak of “long COVID” (“post-COVID” or “COVID long” in French). To date, no pharmacological treatment has been found. The Hôpitaux Universitaires de Genève (HUG) are undertaking a post-COVID study to evaluate the effectiveness of a new immunotherapy drug called temelimab. They are seeking 200 volunteers to take part in this study, as uptake has so far been low.

If you are suffering from post-COVID symptoms and would like to take part in the study, you can find out more on the HUG’s dedicated webpage (in French): https://www.hug.ch/actualite/participez-etude-sur-levaluation-dun-traitement-du-post-covid.